Semax: What the Research Says
Regulatory notice: Semax is currently classified as an FDA Category 2 bulk drug substance. As of April 2026, licensed compounding pharmacies are not legally permitted to prepare or dispense it. PepScribe does not currently offer Semax and has no confirmed timeline for availability. This page is for educational purposes only and does not constitute medical advice or an offer to sell any product.
On February 27, 2026, the U.S. Department of Health and Human Services announced an intent to reclassify certain peptides, potentially including Semax. This announcement has not been formally published in the Federal Register and carries no legal effect until it is. Do not interpret this page as confirmation that Semax's legal status has changed or that PepScribe will offer it in the future.
What is Semax?
Semax is a synthetic 7-amino-acid peptide derived from a fragment (amino acids 4–10) of adrenocorticotropic hormone (ACTH). It was developed by Ashmarin, Myasoedov, and colleagues at the Institute of Molecular Genetics of the Russian Academy of Sciences beginning in the 1980s. Semax has been approved in Russia since the 1990s for the treatment of cognitive disorders, stroke recovery, and peptic ulcers.
What makes Semax unusual is that while it's derived from ACTH, it lacks the hormonal (adrenal-stimulating) effects of its parent molecule. Ashmarin et al. demonstrated in a series of publications in Neuroscience and Behavioral Physiology(1995–2005) that the fragment retains neurotropic and neuroprotective properties without triggering cortisol release — which is why researchers have focused on its cognitive and brain-health applications.
How it works (proposed mechanisms)
Neurotrophic factor expression
Research by Dolotov et al. (2006, Neuroscience Letters) demonstrated that Semax significantly increases BDNF expression in rat hippocampus and frontal cortex. BDNF supports neuronal survival, growth, and the formation of new synaptic connections — the biological basis of learning, memory, and cognitive adaptation. The effect was dose-dependent and detectable within hours of administration.
Serotonin and dopamine systems
Studies by Eremin et al. (2004, 2005) published in the Bulletin of Experimental Biology and Medicine demonstrated that Semax modulates serotonin and dopamine metabolism in specific brain regions. The dopamine effect was most pronounced in the striatum and hypothalamus, while serotonin modulation was observed in the frontal cortex. This dual monoamine effect may contribute to its observed influence on mood, motivation, and cognitive function.
Brain tissue protection
Gusev et al. (1997, Zhurnal Nevrologii i Psikhiatrii) published clinical data supporting Semax's neuroprotective properties in stroke patients. Preclinical work by Storozhevykh et al. (2007, Bulletin of Experimental Biology and Medicine) showed reduced oxidative stress in brain tissue, inhibited inflammatory pathways in the CNS, and supported neuronal survival under ischemic conditions. This is the basis for its approved use in stroke recovery in Russia.
Neurotrophin gene regulation
A 2005 study by Agapova et al. in Genetics (Russian) used gene expression profiling to identify over 100 genes affected by Semax administration in rat brain tissue. The affected genes span neurotrophin signaling, immune response, and vascular function pathways. This broad transcriptomic effect suggests a mechanism of action more complex than simple receptor binding.
Most mechanistic data comes from preclinical research and Russian clinical studies. Western peer-reviewed data is limited, and large-scale international clinical trials have not been completed.
What the research suggests
Semax has decades of pharmaceutical use in Russia with published clinical data. Much of the clinical literature is in Russian-language journals, though key findings have been translated and published in English-language databases.
Cognitive performance
Ashmarin et al. (1995, 2005, Neuroscience and Behavioral Physiology) published multiple studies demonstrating improved attention, memory consolidation, and mental processing speed in both preclinical and early clinical settings. Rat models showed improved performance in learning and memory tasks including conditioned avoidance and maze navigation. Western replication of these cognitive studies is limited.
Stroke recovery
Gusev et al. (1997) published clinical data from stroke patients showing that Semax administered intranasally within 6–12 hours of ischemic stroke reduced infarct progression and improved functional outcomes compared to controls. A follow-up study by Gusev and Skvortsova (2001) in a larger cohort supported these findings. This remains its most clinically validated application and the basis for its Russian pharmaceutical approval.
Neuroprotection
Storozhevykh et al. (2007, Bulletin of Experimental Biology and Medicine) showed that Semax protects cultured neurons from glutamate-induced excitotoxicity and oxidative damage. Animal models of neurodegenerative conditions show some promise in the Russian literature, though this research is early-stage and far from validated for human neurodegenerative disease treatment.
ADHD and attention research
Russian clinical research by Kopelevich and Gromova (2005) explored Semax in children with attention deficits, reporting improvements in attention span, task completion, and cognitive function scores. These findings were published in Russian-language journals and have not been replicated in international peer-reviewed trials with Western methodology.
Administration (research context)
In its approved pharmaceutical form in Russia, Semax is administered as a nasal spray (0.1% or 1% solution). Intranasal delivery provides direct access to the central nervous system, which is particularly relevant for a peptide with neurological targets. The nasal spray format also makes it more practical than injection-based peptides.
Research dosing varies by indication, with different protocols studied for cognitive support vs. stroke recovery. No standardized dosing has been established through international regulatory processes.
This is research context, not prescribing guidance. PepScribe does not currently offer Semax and this information should not be interpreted as a dosing recommendation.
Side effects & safety considerations
Based on the available data from Russian pharmaceutical use and published research.
Reported side effects
- •Nasal irritation or dryness (with intranasal use)
- •Headache (typically mild and transient)
- •Occasional dizziness
Safety profile notes
Despite being derived from ACTH, Semax does not stimulate adrenal cortisol release at therapeutic doses — a distinction established by Ashmarin et al. (1995) and confirmed in subsequent pharmacological studies. The Russian pharmaceutical safety record spans over 25 years of clinical use. Preclinical toxicology studies reported no mutagenic, carcinogenic, or teratogenic effects. Western validation through large-scale international trials is absent.
Consult a healthcare provider before considering any peptide therapy. This information is educational and does not replace medical advice.
Legal status
Semax is on the FDA's Category 2 list in the United States. Licensed compounding pharmacies cannot legally prepare or dispense it as of April 2026.
It is approved as a pharmaceutical in Russia for cognitive disorders, stroke recovery, and peptic ulcers. In the US, it has no FDA drug approval, and its Category 2 bulk substance classification prevents compounding.
Reclassification to Category 1 is expected as part of the broader HHS peptide review announced February 27, 2026, but no formal regulatory action has been finalized. Gray-market products labeled as Semax are unregulated research chemicals without pharmaceutical-grade quality assurance.
While Semax isn't available, these physician-prescribed options may support cognitive and neuroprotective goals
Brain energy, cellular repair, and cognitive support — through legally available, pharmacy-compounded therapies prescribed by a licensed clinician.
NAD+
Supports cellular energy production, cognitive function, and neuroprotection. NAD+ is fundamental to brain energy metabolism and the sirtuins that protect neuronal DNA. Physician-prescribed and delivered to your door.
Get started →Sermorelin
Growth hormone-releasing peptide. GH supports deep sleep (when the brain consolidates memory), cognitive recovery, and neuronal repair processes. Physician-prescribed.
Get started →Get notified when Semax becomes available
Be the first to know when Semax becomes available through PepScribe. We'll email you when Semax becomes legally available through US compounding pharmacies — no spam, no selling your data.
We're building the clinical and pharmacy infrastructure now so we can offer Semax from day one of reclassification.
Deep dives on Semax
Research-backed articles covering specific topics in depth.